Biocytogen Pharmaceuticals (Beijing) Co Ltd

Biocytogen Pharmaceuticals has a market capitalization of 5.45 billion CNY, with a market price of 49.22 CNY per share. The company has 110,781,920 basic and diluted shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company's profitability and returns are not yet established in the valuation snapshot, as no data on return on invested capital (ROIC), gross margins, or operating margins are available. This lack of data makes it difficult to compare Biocytogen Pharmaceuticals to the median performance of its industry peers, particularly in the Biotechnology & Medical Research sector.

Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. This absence of segmental and geographic breakdown limits the ability to assess exposure to specific markets or product lines, which is a key consideration in the Biotechnology & Medical Research industry.

Looking ahead, the company is expected to grow its revenue to 1.94 billion CNY, according to analyst estimates. This represents a significant increase from its current performance, though the exact current revenue figure is not disclosed. The mean EPS estimate of 0.77 CNY suggests a positive earnings outlook, but again, the current EPS is not available for comparison.

The risk assessment indicates a low dilution risk, with no immediate pressure from share issuance or convertible instruments. However, the lack of balance-sheet data and going-concern language in source documents raises concerns about the company's liquidity position. This uncertainty could affect the company's ability to meet short-term obligations and fund operations.

Recent events and filings do not provide specific details on the company's strategic moves or operational developments. The absence of recent transcripts or filings limits the ability to assess the company's current direction and management's outlook.

Revenue ¥980.5M, +36,8% YoY; Operating income +160,8% YoY.

• ▍Revenue ¥980.5M, +36,8% YoY
• ▍Operating income +160,8% YoY
• ▍Net income +108,8% YoY
• ▍Free cash flow +151,8% YoY
• ▍Net margin 3.4%

Revenue ¥716.9M, +34,3% YoY; Operating income +49,0% YoY.

• ▍Revenue ¥716.9M, +34,3% YoY
• ▍Operating income +49,0% YoY
• ▍Net income +36,4% YoY
• ▍Free cash flow +52,2% YoY
• ▍Net margin -53.4%

Revenue ¥533.9M, +50,6% YoY; Operating income −4,9% YoY.

• ▍Revenue ¥533.9M, +50,6% YoY
• ▍Operating income −4,9% YoY
• ▍Net income −10,3% YoY
• ▍Free cash flow −8,5% YoY
• ▍Net margin -112.7%